To report the outcome of localized gastric lymphoma treated with radiation therapy.
Results:
The median follow-up period was 58 months (range, 6.0-120.0). Local recurrence occurred in only 2 patients with MALT lymphoma. No distant recurrence was observed. Local recurrence rate in MALT lymphoma was 91% at 1 year, 91% at 3 years. In acute adverse events, 5 patients had grade 3 white blood cell decreased, 1 patient had grade 4 white blood cell decreased and platelet count decreased, and 1 patient had grade 3 anorexia. One patient with MALT lymphoma could not achieve the planned radiation therapy because of grade 4 white blood cell decreased and platelet count decreased. There was no grade 3 or greater late adverse events. One patient with MALT lymphoma suffered from gastric cancer, and underwent endoscopic excision. No patients died of gastric lymphoma. One patient died of lung cancer.
Conclusion:
Radiation therapy for localized gastric lymphoma was safe and effective. Our result was similar to previous reports.
EP-1140
Role of radiotherapy in treatment of Hodgkin and non Hodgkin lymphomas -our experience D. Scepanovic there were 20 pts with stage I, 17 with stage II, 7 with stage III and 17 pts with stage IV. Sixty-nine percent of pts had favorable HL and 81% of pts nodular sclerosis as histological type. Sixty-four percent of pts with NHL had aggressive disease. Three dimensional conformal radiotherapy has been planned by computed tomography (CT) alone or by 18-FDG positron emission tomography/CT (18-FDG PET/CT). Mostly, patients received chemotherapy (95%) before RT. However, 67% of pts with NHL did not receive rituximab.Whole group of our pts have been irradiated by involved field radiotherapy (IFRT). Most of patients received 36Gy (1.8-2Gy daily) (71%) and 29% more than 36Gy, in both groups.
Results: Median follow-up time was 8 years. Among patients with HL, 33 pts (12%) had relapse and 11 pts (18%) with NHL. Relapses occur most often outside of irradiated volume in both groups of pts. Twenty five percent with HL patients had toxicity, most commonly pulmonary and 7% pts with NHL. During the median time of 13.5 years the incidence of a secondary malignancies (SM) was 3% in pts with HL and 2% with NHL. In group who had HL 91% of these pts lived and 74% in group with NHL. Ten-years DFS was 89% (HL) and 74% (NHL) and 10-years OS was 91% (HL) and 82% (NHL).
Conclusion:
Radiotherapy had an important place in the treatment of our patients with HL, as well as in a group of NHL with acceptable toxicity and incidence of secondary malignancies. 
EP-1141 Second cancer in Primary Mediastinal

Material and Methods:
Between 1991 and December 2006, 107 consecutive untreated patients (pts) with PMBCL were treated at our Departments. Ninety-two/107 pts were evaluable for the second cancer incidence. All patients were treated with standard Methotrexate, Adriamycin, Cyclophosphamide, Vincristine, Prednisone and Bleomycin (MACOP-B) ± Rituximab; all patients underwent mediastinal radiation therapy (RT) at a dose of 30-36 Gy.
Results: At the end of combined treatment, the overall response rate (ORR) including CR+Cru/PR was 91.3% while 7 (7.6 %) patients showed progressive disease. Nine/84 (9.7%) patients relapsed within 10 months (range 3-10 months) from the end of therapy. After a median follow-up of 142 months (1-212 months), the actuarial 15-year OS and PFS were 87% and 84%, respectively. We recorded secondary malignancies in 3/80 long-surviving patients (3.75%) with cumulative incidence of thyroid and A acute myeloid leukemia of 3.47 at 15 years and with a 20-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a Standardized Incidence Ratio of 7.97 and with an Absolute Excess Risk of 17. 84. Moreover, we observed 1 Acute Myeloid Leukemia ( AML) versus 0.015 expected cases with a SIR of 66.53 and with an AER of 10.05. No breast cancer occurred Conclusion: Combined modality treatment of chemotherapy± with/without Rituximab and mediastinal RT was related to a
